The economics of benign prostatic hyperplasia treatment

A literature review

Michael A. Kortt, J Lyle Bootman

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common benign neoplasms in elderly men in the United States; it has been estimated that the annual costs of caring for these men exceed $4 billion. This condition is rarely life threatening, but often affects the individual's quality of life in varying degrees. There are several treatments for this condition, including surgery, with the most common procedure being transurethral resection of the prostate. Other treatment options include medication (such as finasteride and terazosin), balloon dilation, and watchful waiting. The cost associated with BPH depends on the severity of the disease and the appropriate course of treatment. The objective of this paper is to identify and evaluate the economic research papers that have considered either the economic burden or costs associated with alternative BPH therapy options and to identify key areas for future economic research. This review indicates that the economic studies of BPH are diverse in nature and greater attention needs to be placed on the societal appraisal of competing BPH therapies. Other research areas include the economic analysis of both short- and long-run BPH treatment options, increased cost-utility analysis, and the use of retrospective claims database analysis using regression techniques.

Original languageEnglish (US)
Pages (from-to)1227-1241
Number of pages15
JournalClinical Therapeutics
Volume18
Issue number6
DOIs
StatePublished - 1996

Fingerprint

Prostatic Hyperplasia
Economics
Terazosin
Costs and Cost Analysis
Therapeutics
Research
Insurance Claim Review
Watchful Waiting
Finasteride
Transurethral Resection of Prostate
Cost-Benefit Analysis
Dilatation
Quality of Life
Databases
Neoplasms

ASJC Scopus subject areas

  • Pharmacology

Cite this

The economics of benign prostatic hyperplasia treatment : A literature review. / Kortt, Michael A.; Bootman, J Lyle.

In: Clinical Therapeutics, Vol. 18, No. 6, 1996, p. 1227-1241.

Research output: Contribution to journalArticle

@article{ed4986c6be3c43d19a7855ea751064c8,
title = "The economics of benign prostatic hyperplasia treatment: A literature review",
abstract = "Benign prostatic hyperplasia (BPH) is one of the most common benign neoplasms in elderly men in the United States; it has been estimated that the annual costs of caring for these men exceed $4 billion. This condition is rarely life threatening, but often affects the individual's quality of life in varying degrees. There are several treatments for this condition, including surgery, with the most common procedure being transurethral resection of the prostate. Other treatment options include medication (such as finasteride and terazosin), balloon dilation, and watchful waiting. The cost associated with BPH depends on the severity of the disease and the appropriate course of treatment. The objective of this paper is to identify and evaluate the economic research papers that have considered either the economic burden or costs associated with alternative BPH therapy options and to identify key areas for future economic research. This review indicates that the economic studies of BPH are diverse in nature and greater attention needs to be placed on the societal appraisal of competing BPH therapies. Other research areas include the economic analysis of both short- and long-run BPH treatment options, increased cost-utility analysis, and the use of retrospective claims database analysis using regression techniques.",
author = "Kortt, {Michael A.} and Bootman, {J Lyle}",
year = "1996",
doi = "10.1016/S0149-2918(96)80078-6",
language = "English (US)",
volume = "18",
pages = "1227--1241",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - The economics of benign prostatic hyperplasia treatment

T2 - A literature review

AU - Kortt, Michael A.

AU - Bootman, J Lyle

PY - 1996

Y1 - 1996

N2 - Benign prostatic hyperplasia (BPH) is one of the most common benign neoplasms in elderly men in the United States; it has been estimated that the annual costs of caring for these men exceed $4 billion. This condition is rarely life threatening, but often affects the individual's quality of life in varying degrees. There are several treatments for this condition, including surgery, with the most common procedure being transurethral resection of the prostate. Other treatment options include medication (such as finasteride and terazosin), balloon dilation, and watchful waiting. The cost associated with BPH depends on the severity of the disease and the appropriate course of treatment. The objective of this paper is to identify and evaluate the economic research papers that have considered either the economic burden or costs associated with alternative BPH therapy options and to identify key areas for future economic research. This review indicates that the economic studies of BPH are diverse in nature and greater attention needs to be placed on the societal appraisal of competing BPH therapies. Other research areas include the economic analysis of both short- and long-run BPH treatment options, increased cost-utility analysis, and the use of retrospective claims database analysis using regression techniques.

AB - Benign prostatic hyperplasia (BPH) is one of the most common benign neoplasms in elderly men in the United States; it has been estimated that the annual costs of caring for these men exceed $4 billion. This condition is rarely life threatening, but often affects the individual's quality of life in varying degrees. There are several treatments for this condition, including surgery, with the most common procedure being transurethral resection of the prostate. Other treatment options include medication (such as finasteride and terazosin), balloon dilation, and watchful waiting. The cost associated with BPH depends on the severity of the disease and the appropriate course of treatment. The objective of this paper is to identify and evaluate the economic research papers that have considered either the economic burden or costs associated with alternative BPH therapy options and to identify key areas for future economic research. This review indicates that the economic studies of BPH are diverse in nature and greater attention needs to be placed on the societal appraisal of competing BPH therapies. Other research areas include the economic analysis of both short- and long-run BPH treatment options, increased cost-utility analysis, and the use of retrospective claims database analysis using regression techniques.

UR - http://www.scopus.com/inward/record.url?scp=0030512093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030512093&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(96)80078-6

DO - 10.1016/S0149-2918(96)80078-6

M3 - Article

VL - 18

SP - 1227

EP - 1241

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -